Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated ...

In conclusion, this study developed a novel cyclic peptide antagonist that targets intestinal FXR and disrupts FXR-co-activator interactions, serving as a promising therapeutic approach for MASH ...

A famed graphic novelist returns! A Southern-gothic crime-thriller inspired by The Godfather! An extremely in depth biography ...

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from ...

The MASH landscape has changed dramatically since ... late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases.

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns.

MASH is marked by lipid droplet accumulation ... potentially leading to novel strategies to combat this growing public health issue,” concludes Dr. Yamada.

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...

Her tall tales of alligator wrestlers in Florida, homesteaders on the Gothic Great Plains and female prospectors digging for gold mash up history ... into an opera. The novel is framed by two ...

Current assessments, such as the NAFLD Fibrosis Score, for example, are not sensitive enough to detect early-stage MASH. Novel biomarkers that employ imaging, such as LiverMultiScan, show promise ...